IP Library Granted Patent US 10,238,451
Granted Patent B2
US 10,238,451 · App. 14/285,627 · Granted Mar 26, 2019

Apparatus and methods to modulate bladder function

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,238,451
App. No.
14/285,627
Granted
Mar 26, 2019
Kind
B2
Abstract

Apparatus and methods are provided to concentrate energy delivery in non-superficial target tissue within a trigone region of a human bladder wall to modulate bladder function.

Claims (17)

1. A method of modulating bladder function, the method comprising:

maintaining needle electrodes of an energy delivery device within bladder wall tissue using the energy delivery device positioned in a vagina of a patient; and

activating the needle electrodes within the bladder wall tissue while the energy delivery device is positioned in the vagina to disrupt afferent nerve signals associated with bladder function by applying ablative thermal energy from the needle electrodes of the energy delivery device to a targeted portion of the bladder wall tissue at a selected depth from an inner wall of the vagina.

2. The method of claim 1 , wherein the applying ablative thermal energy from the needle electrodes of the energy delivery device to the targeted portion of the bladder wall tissue at the selected depth from the inner wall of the vagina comprises applying RF energy using the needle electrodes to the portion of the bladder wall tissue.

3. The method of claim 1 , wherein the applying ablative thermal energy from the needle electrodes of the energy delivery device to the targeted portion of the bladder wall tissue at the selected depth from the inner wall of the vagina comprises ablating afferent nerves emanating from the bladder.

4. The method of claim 1 , wherein the applying ablative thermal energy from the needle electrodes of the energy delivery device to the targeted portion of the bladder wall tissue at the selected depth from the inner wall of the vagina comprises applying the ablative thermal energy to targeted nerves proximate a trigone region of the bladder.

5. The method of claim 1 , wherein proximal portions of the needle electrodes include an electrically insulative coating such that the ablative thermal energy does not flow between the proximal portions of the needle electrodes.

6. The method of claim 1 , wherein the energy delivery device is advanced into the vagina while steering the energy delivery device.

7. The method of claim 1 , wherein the needle electrodes comprise a pair of needle electrodes that are oriented parallel to one another.

8. The method of claim 1 , wherein the needle electrodes consist of a pair of needle electrodes that are oriented parallel to one another.

9. The method of claim 1 , further comprising penetrating the needle electrodes through a mucosal surface of the vagina.

10. The method of claim 1 , wherein the method treats an overactive bladder condition of the patient.

11. The method of claim 1 , wherein said applying ablative thermal energy from the needle electrodes of the energy delivery device to the targeted portion of the bladder wall tissue at the selected depth from the inner wall of the vagina comprises applying the ablative thermal energy to targeted nerves in a trigone region of the bladder.

12. The method of claim 1 , further comprising, visualizing, using an imaging system, a position of the energy delivery device within the vagina.

13. The method of claim 1 , further comprising, after the energy delivery device is positioned in the vagina, deploying the needle electrodes.

14. The method of claim 1 , wherein the targeted portion of the bladder wall tissue is non-superficial tissue of the bladder.

15. The method of claim 1 , wherein said applying ablative thermal energy from the needle electrodes of the energy delivery device to the targeted portion of the bladder wall tissue at the selected depth from the inner wall of the vagina comprises avoiding damage to the superficial mucosal layer of the bladder wall tissue.

Assignments (4)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 14, 2019
From: HOLOGIC, INC.; CYNOSURE, LLC; CYTYC CORPORATION; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 050719/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2019
From: AMPHORA MEDICAL, INC.
To: HOLOGIC, INC.,
Reel/Frame 049786/0138 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2018
From: SACHS, DAN; HLAVKA, EDWIN J.
To: AMPHORA MEDICAL, INC.
Reel/Frame 044974/0286 →
Cited By (1)
US 12,397,156